决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Erratum: Ligand-based, piggyBac-engineered CAR-T cells targeting EGFR are safe and effective against non-small cell lung cancers.
本文对文章 DOI: 10.1016/j.omto.2023.100728 进行了更正。
勘误:本文更正DOI为10.1016/j.omto.2023.100728的文章。
[This corrects the article DOI: 10.1016/j.omto.2023.100728.].
MEMBER ACCOUNT
登录成功会直接打开下一页。